Search results for "Chronic heart failure"

showing 10 items of 15 documents

Cardiopulmonary Exercise Testing in Patients with Chronic Heart Failure: Prognostic Comparison from Peak VO2 and VE/VCO2 Slope

2010

Background: Cardiopulmonary exercise testing with ventilatory expired gas analysis (CPET) has proven to be a valuable tool for assessing patients with chronic heart failure (CHF). The maximal oxygen uptake (peak V02) is used in risk stratification of patients with CHF. The minute ventilation-carbon dioxide production relationship (VE/VCO2 slope) has recently demonstrated prognostic significance in patients with CHF. Methods: Between January 2006 and December 2007 we performed CPET in 184 pts (146 M, 38 F, mean age 59.8 ± 12.9 years), with stable CHF (96 coronary artery disease, 88 dilated cardiomyopathy), in NYHA functional class II (n.107) - III (n.77), with left ventricular ejection frac…

Congestive heart failuremedicine.medical_specialtygas exchangeArticleCoronary artery diseaseInternal medicineMedicineEjection fractionReceiver operating characteristicbusiness.industryventilationVO2 maxDilated cardiomyopathyCARDIOPULMONARY CHRONIC HEART FAILUREmedicine.diseaseexercise capacityLog-rank testprognosis.Heart failureBreathingCardiologyPhysical therapyCardiology and Cardiovascular Medicinebusinesshuman activitiescirculatory and respiratory physiologyThe Open Cardiovascular Medicine Journal
researchProduct

Do the current guidelines for heart failure diagnosis and treatment fit with clinical complexity?

2022

Heart failure (HF) is a clinical syndrome defined by specific symptoms and signs due to structural and/or functional heart abnormalities, which lead to inadequate cardiac output and/or increased intraventricular filling pressure. Importantly, HF becomes progressively a multisystemic disease. However, in August 2021, the European Society of Cardiology published the new Guidelines for the diagnosis and treatment of acute and chronic HF, according to which the left ventricular ejection fraction (LVEF) continues to represent the pivotal parameter for HF patients’ evaluation, risk stratification and therapeutic management despite its limitations are well known. Indeed, HF has a complex pathophys…

Left ventricular ejection fractiontherapyacute heart failureheart failure left ventricular ejection fraction New York Heart Association classification acute heart failure chronic heart failure phenotypes pathophysiology therapyAcute heart failure; Chronic heart failure; Heart failure; Left ventricular ejection fraction; New York Heart Association classification; Pathophysiology; Phenotypes; TherapyRphenotypesAcute heart failureheart failureHeart failureleft ventricular ejection fractionGeneral MedicineNew York Heart Association classificationPathophysiologyChronic heart failurechronic heart failurePhenotypesMedicineTherapyacute heart failure; chronic heart failure; heart failure; left ventricular ejection fraction; new york heart association classification; pathophysiology; phenotypes; therapypathophysiology
researchProduct

Multiple hormonal and metabolic deficiency syndrome in chronic heart failure: rationale, design, and demographic characteristics of the T.O.S.CA. Reg…

2018

Recent evidence supports the concept that progression of chronic heart failure (CHF) depends upon an imbalance of catabolic forces over the anabolic drive. In this regard, multiple hormonal deficiency syndrome (MHDS) significantly has impacts upon CHF progression, and is associated with a worse clinical status and increased mortality. The T.O.S.CA. (Trattamento Ormonale nello Scompenso CArdiaco; Hormone Therapy in Heart Failure) Registry (clinicaltrial.gov = NCT02335801) tests the hypothesis that anabolic deficiencies reduce survival in a large population of mild-to-moderate CHF patients. The T.O.S.CA. Registry is a prospective multicenter observational study coordinated by “Federico II” Un…

MaleAnabolismmedicine.medical_treatment030204 cardiovascular system & hematologylaw.invention0302 clinical medicineRandomized controlled triallawClinical endpointMedicineDeficiency Disease030212 general & internal medicineProspective StudiesRegistriesProspective cohort studyTestosteroneAnabolic deficiency; Chronic heart failure; Heart failure metabolism; Multiple hormonal deficiency syndrome; Registry; Aged; Biomarkers; Chronic Disease; Deficiency Diseases; Disease Progression; Female; Heart Failure; Humans; Italy; Male; Metabolic Diseases; Middle Aged; Prospective Studies; Registries; Internal Medicine; Emergency MedicineMiddle AgedItalyEmergency MedicineDisease ProgressionFemaleHumanmedicine.medical_specialtyRegistryAnabolic deficiencyAnabolic deficiency Chronic heart failure Heart failure metabolism Multiple hormonal deficiency syndrome RegistrySocio-culturaleHeart failure metabolism03 medical and health sciencesMetabolic DiseasesInternal medicineInternal MedicineHumansAgedHeart Failurebusiness.industryMultiple hormonal deficiency syndromeSettore MED/13 - ENDOCRINOLOGIABiomarkermedicine.diseaseChronic heart failureMetabolic DiseaseProspective StudieHeart failureChronic DiseaseObservational studyHormone therapybusinessDeficiency DiseasesBiomarkersInternal and emergency medicine
researchProduct

Hypertonic Saline in Conjunction with High-Dose Furosemide Improves Dose-Response Curves in Worsening Refractory Congestive Heart Failure.

2015

Introduction Diuretic responsiveness in patients with chronic heart failure (CHF) is better assessed by urine production per unit diuretic dose than by the absolute urine output or diuretic dose. Diuretic resistance arises over time when the plateau rate of sodium and water excretion is reached prior to optimal fluid elimination and may be overcome when hypertonic saline solution (HSS) is added to high doses of furosemide. Methods Forty-two consecutively hospitalized patients with refractory CHF were randomized in a 1:1:1 ratio to furosemide doses (125 mg, 250 mg, 500 mg) so that all patients received intravenous furosemide diluted in 150 ml of normal saline (0.9%) in the first step (0–24 h…

MaleDose–response curves; Furosemide; Heart failure; Hypertonic saline; Refractory chronic heart failure; Pharmacology (medical); Medicine (all)medicine.medical_treatmentSodiumchemistry.chemical_elementHypertonic salineRefractoryDrug toleranceFurosemidemedicineRefractory chronic heart failureHumansPharmacology (medical)DiureticsAgedOriginal ResearchMedicine(all)Aged 80 and overHeart FailureSaline Solution HypertonicDose-Response Relationship Drugbusiness.industryMedicine (all)Osmolar ConcentrationSodiumFurosemideGeneral MedicineDrug ToleranceMiddle Agedmedicine.diseaseHypertonic salineDose–response relationshipchemistryHeart failureAnesthesiaChronic DiseaseDrug Therapy CombinationFemaleDiureticDose–response curvebusinessDose–response curvesmedicine.drugAdvances in therapy
researchProduct

Detectable interleukin-9 plasma levels are associated with impaired cardiopulmonary functional capacity and all-cause mortality in patients with chro…

2016

Inflammatory activation plays a pivotal role in chronic heart failure (CHF) through the increased expression of pro-inflammatory cytokines [1]. Decreased plasma levels of Interleukin (IL-) 5, IL-7 and Interferon-γ (IFN-γ) and increased levels of IL-9 have been already described in CHF [2], and a negative correlation was also reported between IL-9 and left ventricular ejection fraction (LVEF) [2]. Yet, there are only limited data exploring the association between cytokines and functional capacity in CHF and their prognostic role [3]; therefore, primary end-point of the current study was to evaluate all-cause mortality according to changes in cytokines plasma levels in CHF patients.  

Malemedicine.medical_specialty030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineCause of DeathmedicineHumansInterleukin 9030212 general & internal medicineInterleukin 6CytokineInterleukin 5Risk stratificationInterleukin 4OutcomeAgedHeart Failurebiologybusiness.industryRisk FactorInterleukin-9Middle Agedmedicine.diseaseChronic heart failurePeak oxygen consumptionInterleukin 10EndocrinologyInterleukin 15Heart failurebiology.proteinCardiologyFemaleChronic heart failure; Cytokines; Interleukin-9; Outcomes; Peak oxygen consumption; Risk stratification; Cardiology and Cardiovascular MedicineCardiology and Cardiovascular MedicinebusinessInterleukin 1 receptor type IHumanInternational journal of cardiology
researchProduct

Isolation and Characterization of CD276+/HLA-E+ Human Subendocardial Mesenchymal Stem Cells from Chronic Heart Failure Patients: Analysis of Differen…

2012

Mesenchymal stem cells (MSCs) are virtually present in all postnatal organs as well as in perinatal tissues. MSCs can be differentiated toward several mature cytotypes and interestingly hold potentially relevant immunomodulatory features. Myocardial infarction results in severe tissue damage, cardiomyocyte loss, and eventually heart failure. Cellular cardiomyoplasty represents a promising approach for myocardial repair. Clinical trials using MSCs are underway for a number of heart diseases, even if their outcomes are hampered by low long-term improvements and the possible presence of complications related to cellular therapy administration. Therefore, elucidating the presence and role of MS…

Pathologymedicine.medical_specialtyB7 AntigensHeart VentriclesGene ExpressionCell SeparationBiologyCell therapyHLA-EAntigens CDOsteogenesisCellular cardiomyoplastymedicineHumansImmunologic FactorsMyocardial infarctionCells CulturedHeart FailureAdipogenesisMesenchymal stem cells human heart stromal progenitors post-infarct chronic heart failure cardiomyocyte markers immune modulation inflammation cardiac remodelling regenerative medicineSettore BIO/16 - Anatomia UmanaHistocompatibility Antigens Class IMesenchymal stem cellMesenchymal Stem CellsCell BiologyHematologyAnatomymedicine.diseaseClinical trialmedicine.anatomical_structureVentricleHeart failureChondrogenesisBiomarkersDevelopmental BiologyStem Cells and Development
researchProduct

Progressive right ventricular dysfunction and exercise impairment in patients with heart failure and diabetes mellitus: insights from the T.O.S.CA. R…

2022

Abstract Background Findings from the T.O.S.CA. Registry recently reported that patients with concomitant chronic heart failure (CHF) and impairment of insulin axis (either insulin resistance—IR or diabetes mellitus—T2D) display increased morbidity and mortality. However, little information is available on the relative impact of IR and T2D on cardiac structure and function, cardiopulmonary performance, and their longitudinal changes in CHF. Methods Patients enrolled in the T.O.S.CA. Registry performed echocardiography and cardiopulmonary exercise test at baseline and at a patient-average follow-up of 36 months. Patients were divided into three groups based on the degree of insulin impairmen…

RegistrieHeart FailureEndocrinology Diabetes and MetabolismVentricular Dysfunction RightDiabetesInsulinsSocio-culturaleStroke VolumeInsulin resistanceDiabeteCardiopulmonary exercise test Chronic heart failure Diabetes Insulin resistance Right ventricle TOSCA Registry..Chronic heart failureDiabetes Mellitus Type 2TOSCA RegistryExercise TestVentricular Function RightHumansInsulinRight ventricleRegistriesCardiology and Cardiovascular MedicineCardiopulmonary exercise testTOSCAHumanLS4_7
researchProduct

Recent Patents on Oxidative Stress-Related Biomarkers in Chronic Heart Failure: The Central Role of Endothelium and Myeloperoxidase

2013

Endothelial cells are key modulators of multiple physiological processes, and their impairment may result in the generation of endothelial dysfunction and ultimately cardiovascular diseases. Under physiologic conditions, reactive oxygen and nitrogen mediators of endothelial cells act to propagate signals driven by different stimuli, by forming molecules with a longer half-life like hydrogen peroxide. Reactive oxygen species (ROS) are constantly produced as a consequence of aerobic metabolism. Under physiologic conditions, their tendency to cause oxidative damage is counterbalanced by the action of antioxidants or oxidant-scavenging enzymes. An imbalance in favour of oxidants leads to oxidat…

Settore BIO/16 - Anatomia UmanaClinical BiochemistryMolecular MedicineChronic heart failure coronary artery disease diagnostic markers endothelial dysfunction endothelium myeloperoxidase oxidative stress prognostic biomarkers serum assaysRecent Patents on Biomarkers
researchProduct

Effects of oxidative stress on primary human endothelial cells. Potential active contribution of endothelium to inflammatory heart diseases

2007

Settore BIO/16 - Anatomia UmanaMPO endothelium endothelial dysfunction oxidative stress chronic heart failure
researchProduct

Extended characterization of hypoimmunogenic mesenchymal stem cells isolated from the subendocardial layer of human hearts from chronic heart failure…

2009

Purpose: Mesenchymal stem cells (MSC) are pluripotent cells which are known to reside in a number of adult organs. In human heart, various populations of stem/progenitor cells have been isolated by different groups. Several efforts still need to be made to better characterize resident or migrating MSC populations in terms of markers expression and immunogenic potential prior to their use for regenerative medicine applications in heart diseases. Methods: MSC were isolated from the sub-endocardial layer of left ventricle sections of hearts explanted from patients affected by chronic heart failure (CHF). The expression of several markers characteristic of the MSC lineage was assessed at both t…

Settore BIO/16 - Anatomia Umanamesenchymal stem cells chronic heart failure differentiation markers transcription factor immune regulation
researchProduct